All articles by Jay Patel
Jay Patel is a Pharma analyst with GlobalData.
Jay Patel
Industry slow to embrace new fatty liver disease nomenclature
The three societies voted by a supermajority for the shift, justifying their collective decision by suggesting that the new names were less stigmatising and exclusionary than their predecessors.
THR-β agonists emerge as leading drug class in NASH
Just this month, Terns Pharma released results from the Phase IIa DUET trial of its own THR-β agonist TERN-501.